The top executive at Pfizer, the leading maker of the COVID-19 vaccine, has tested positive for the virus and said he is experiencing very mild symptoms.
President and CEO Albert Bourla said Monday that he has begun treatment with Pfizer’s Paxlovid drug and is in isolation while recovering.
Bourla received four shots of Comirnaty, a COVID-19 vaccine developed by the New York-based drugmaker in partnership with BioNTech. He said in a brief statement released by the company that he believes in a speedy recovery.
According to the Centers for Disease Control and Prevention, more than 128 million people in the United States have been fully vaccinated with the Pfizer vaccine since it entered the market more than a year ago, and nearly 61 million people have received the booster shot. original again.
The vaccine still provides solid protection against hospitalizations and serious illness, scientists say. However, the evolution of the virus has made it more difficult for vaccines to prevent all forms of illness from developing.
Pfizer and another vaccine maker, Moderna, are updating their shots to protect against newer versions of the virus for a boosted campaign in the fall.
In research, Paxlovid has also proven to be extremely effective in preventing serious illness if it is used soon after symptoms begin.
Comirnaty and Paxlovid are the best-selling COVID-19 vaccines and treatments on the market. Combined, they brought in nearly $17 billion in revenue for Pfizer in the second quarter that just ended.